Free Trial

12 Stocks Corporate Insiders are Abandoning - 2 of 12

 
 

Neurocrine Biosciences (NASDAQ:NBIX)

Dollar Amount of Shares Sold
$67,341,979.08
Number of Insider Stock Sales in the Last 180 Days
36
Volume of Shares Sold
502,807
Who Sold Shares
Darin Lippoldt (Insider), David W Boyer (Insider), Eiry Roberts (Insider), Eric Benevich (Insider), Gary A Lyons (Director), George J Morrow (Director), Ingrid Delaet (Insider), Kevin Charles Gorman (CEO), Kyle Gano (Insider), Leslie V Norwalk (Director), Matt Abernethy (CFO), Richard F Pops (Director), Shalini Sharp (Director), Stephen A Sherwin (Director) and William H Rastetter (Director)

Insider Trades by Quarter for Neurocrine Biosciences (NASDAQ:NBIX)

About Neurocrine Biosciences

Neurocrine Biosciences logoNeurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids. Read More 
 
 

Do This Before July 30 2024 To Claim Trump’s Gift (Ad)

In January 2021, Donald Trump silently rolled out a special gift to the American public… One that top house republicans called “The Key To America’s Economic Future”.

You just have to make this simple move before July 30, 2024.